Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.49 |
| ▸ | TUBB | P07437 | 3/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038225 | 0.93 | KMT2A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4711333 | 0.92 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4707830 | 0.92 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5037345 | 0.90 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4708995 | 0.87 | CHRM1 (0.46) | KMT2ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL4708083 | 0.86 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4707917 | 0.86 | KMT2A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4709805 | 0.85 | CREBBP (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5349947 | 0.84 | GABRA1 (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4709678 | 0.83 | KMT2A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | claimed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | claimed |
| JP-2006509832-A | — | — | 2006-03-23 | — | — | JP | claimed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | claimed |
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | TUBB4A 2731/4885TUBB 2336/4885TUBA3C 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.